Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Upadacitinib ER by AbbVie for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease): Likelihood of Approval
Upadacitinib ER is under clinical development by AbbVie and currently in Pre-Registration for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease)....
Venetoclax by AbbVie for Secondary Acute Myeloid Leukemia: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase II for Secondary Acute Myeloid Leukemia. According to GlobalData,...
Venetoclax by AbbVie for Aplastic Anemia: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase II for Aplastic Anemia. According to GlobalData, Phase II...
Venetoclax by AbbVie for Mantle Cell Lymphoma: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase III for Mantle Cell Lymphoma. According to GlobalData, Phase...
Ibrutinib by AbbVie for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Ibrutinib is under clinical development by AbbVie and currently in Phase III for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid...
Ibrutinib by AbbVie for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Ibrutinib is under clinical development by AbbVie and currently in Phase III for Splenic Marginal Zone B-Cell Lymphoma. According to...
Ibrutinib by AbbVie for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Ibrutinib is under clinical development by AbbVie and currently in Phase III for Nodal Marginal Zone B-Cell Lymphoma. According to...
Navitoclax dihydrochloride by AbbVie for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval
Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase III for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). According...
Venetoclax by AbbVie for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...
Venetoclax by AbbVie for Myeloproliferative Disorders: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase II for Myeloproliferative Disorders. According to GlobalData, Phase II...
Venetoclax by AbbVie for Solid Tumor: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Venetoclax by AbbVie for Amyloidosis: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase II for Amyloidosis. According to GlobalData, Phase II drugs...
Elsubrutinib by AbbVie for Systemic Lupus Erythematosus: Likelihood of Approval
Elsubrutinib is under clinical development by AbbVie and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...
Telisotuzumab vedotin by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval
Telisotuzumab vedotin is under clinical development by AbbVie and currently in Phase III for Non-Small Cell Lung Cancer. According to...
Risk adjusted net present value: What is the current valuation of AbbVie's Navitoclax dihydrochloride?
Navitoclax dihydrochloride is a small molecule commercialized by AbbVie, with a leading Phase III program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET...
Risk adjusted net present value: What is the current valuation of AbbVie's Lutikizumab?
Lutikizumab is a monoclonal antibody commercialized by AbbVie, with a leading Phase III program in Hidradenitis Suppurativa. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of AbbVie's Emraclidine?
Emraclidine is a small molecule commercialized by AbbVie, with a leading Phase II program in Schizophrenia. According to Globaldata, it...
Risk adjusted net present value: What is the current valuation of AbbVie's Pivekimab sunirine?
Pivekimab sunirine is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase II program in Acute Lymphocytic Leukemia...
Risk adjusted net present value: What is the current valuation of AbbVie's Tavapadon?
Tavapadon is a small molecule commercialized by AbbVie, with a leading Phase III program in Parkinson's Disease. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of AbbVie's Telisotuzumab Vedotin?
Telisotuzumab Vedotin is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase III program in Non-Small Cell Lung...